Key result
Combined modality treatment for non-metastatic extraskeletal Ewings sarcoma resulted in 3-year and 5-year overall survival rates of 60% and 30%, respectively, with the VAC/IE chemotherapy regimen predicting prolonged survival.
Why the study?
Does combined modality treatment improve survival in patients with extraskeletal Ewings sarcoma?
Observational (n=19)
No
Does combined modality treatment improve survival in patients with extraskeletal Ewings sarcoma?
Aggressive combination chemotherapy followed by complete surgery or radiotherapy to a dose of more than 50 Gy is essential for optimal outcomes in extraskeletal Ewings sarcoma.
Answers are grounded in this paper and cite their sources.
May support VAC/IE-based combined modality therapy in non-metastatic extraskeletal Ewing sarcoma; hypothesis-generating and requires prospective validation.
BACKGROUND: Extraskeletal Ewings sarcoma are rare tumors for which there is no consensus on optimal management. METHODS: A retrospective review of the clinical features, treatment and outcome of patients with extraskeletal Ewings sarcoma who reported to a single institution between January 1992-December 2003 is reported. RESULTS: A total of 19 patients with extraskeletal Ewings sarcoma were identified. Of these, 4 patients had metastatic disease at presentation and 15 patients with non-metastatic disease received combined modality treatment with primary combination chemotherapy followed by local treatment with radiotherapy or surgery. Disease free survival and overall survival for patients with non metastatic disease after combined modality treatment were 60% and 30% respectively. The significant predictors for prolonged disease free survival and overall survival were high haemoglobin (p = 0.002), low lactate dehydrogenase (p = 0.028), chemotherapy with Vincristine, Adriamycin, Cyclophosphamide, Ifosfamide and Etoposide regime (p = 0.008) and complete response to chemotherapy (p = 0.001). CONCLUSION: Aggressive combination chemotherapy followed by complete surgery or radiotherapy to a dose of more than 50 Gy is essential to confer optimal outcome for patients with extraskeletal Ewings sarcoma.
No takes yet. Share an insight, caveat, or question.
Venkitaraman et al. (2007) conducted an observational in Extraskeletal Ewings sarcoma (n=19). Combined modality treatment (chemotherapy and surgery/radiotherapy) was evaluated on 3-year overall survival in non-metastatic patients. Combined modality treatment for non-metastatic extraskeletal Ewings sarcoma resulted in 3-year and 5-year overall survival rates of 60% and 30%, respectively, with the VAC/IE chemotherapy regimen predicting prolonged survival.
Synapse has enriched 10 related papers. Consider them for comparative context: